(CercleFinance.com) – Valbiotis gained more than 4% in Paris while Oddo BHF maintained its ‘outperformance’ rating on the stock, with a price target raised from 10 to 11.5 euros.
As a reminder, Valbiotis published its phase II/III clinical results of TOTUM-63 in prediabetes earlier this week. These turn out to be positive demonstrating a statistically significant reduction in patients’ fasting blood glucose vs. placebo.
According to Oddo BHF, the commercialization of TOTUM-63 is already planned, given its health nutrition status, in 2024, in collaboration with Nestlé Health Science.
‘Thus we see the clinical and regulatory now secure. By virtue of its profile, Valbiotis combines the opportunities of a biotechnology company with a lower development risk, which makes it more attractive’, concludes the broker.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
